Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 10/20 | 0.57 |
| ▸ | DRD2 | P14416 | 2/20 | 0.53 |
| ▸ | DRD3 | P35462 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.51 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3521678 | 1.00 | DRD4 (0.57) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL3519935 | 1.00 | DRD4 (0.57) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL12610726 | 0.98 | DRD4 (0.56) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL12610644 | 0.98 | DRD4 (0.56) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL917642 | 0.98 | DRD4 (0.56) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL4836218 | 0.98 | DRD4 (0.56) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL27641050 | 0.91 | DRD4 (0.57) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL4129378 | 0.90 | DRD4 (0.56) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL12696566 | 0.90 | DRD4 (0.56) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL2447401 | 0.90 | DRD4 (0.56) | DRD4DRD2DRD3CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103923765-A | Detergent Composition For Process Of Manufacturing Semiconductors And Displays | COWON INNOTECH INC | 2014-07-16 | — | — | CN | claimed |
| US-7109243-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2006-09-19 | — | — | US | claimed |
| US-12630556-B2 | Substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as PDE2 inhibitors | DART NEUROSCIENCE LLC (US) | 2026-05-19 | — | — | US | disclosed |
| US-12552796-B2 | EED inhibitor, and preparation method therefor and use thereof | JING MEDICINE TECHNOLOGY (SHANGHAI) LTD. (CN) | 2026-02-17 | — | — | US | disclosed |
| EP-3980401-B1 | PURINE DERIVATIVES, AS NR2B NEGATIVE MODULATORS AND THE USE THEREOF AS MEDICAMENT, IN PARTICULAR FOR TREATING DEPRESSIVE DISORDERS | BOEHRINGER INGELHEIM INT (DE) | 2026-01-28 | — | — | EP | disclosed |
| US-12522618-B2 | Copper complexes for treatment of neurodegenerative disorders | ALS THERAPY DEVELOPMENT INSTITUTE (US) | 2026-01-13 | — | — | US | disclosed |
| EP-4056570-B1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | UNIV SHANGHAI TECHNOLOGY (CN) | 2026-01-07 | — | — | EP | disclosed |
| EP-4626865-A1 | CYCLIC PYRAZOLE DIAMIDE IRE1/XBP1S ACTIVATORS | Protego Biopharma, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| US-20250092047-A1 | SUBSTITUTED [1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE LLC | 2025-03-20 | — | — | US | disclosed |
| US-20240368195-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | ALS THERAPY DEVELOPMENT INST (US) | 2024-11-07 | — | — | US | disclosed |
| US-20240309003-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2024-09-19 | — | — | US | disclosed |
| CN-1889940-A | Treatment of personality changes due to hot flashes, impulse control disorders and systemic medical conditions | LILLY CO ELI (US) | 2007-01-03 | — | — | CN | disclosed |
| CN-1878762-A | Morpholine derivatives as norepinephrine reuptake inhibitors | LILLY CO ELI (US) | 2006-12-13 | — | — | CN | disclosed |
| US-7109243-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2006-09-19 | — | — | US | disclosed |
| US-20050222139-A1 | Non-peptide gnrh antagonists | FERRING B.V. (NL) | 2005-10-06 | — | — | US | disclosed |
| CN-1662498-A | Novel tetrahydropyridine derivatives as renin inhibitors | ACTELION PHARMACEUTICALS LTD (CH) | 2005-08-31 | — | — | CN | disclosed |
| EP-1485356-A1 | NON-PEPTIDE GnRH ANTAGONISTS | Ferring BV (NL) | 2004-12-15 | — | — | EP | disclosed |
| WO-2004084842-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2004-10-07 | — | — | WO | disclosed |
| US-20040198780-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2004-10-07 | — | — | US | disclosed |
| WO-2003078398-A1 | NON-PEPTIDE GnRH ANTAGONISTS | FERRING BV (NL) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222139-A1 | Non-peptide gnrh antagonists | GNRHR, BRS3, FSHR | DRD4 248/4885DRD2 261/4885DRD3 121/4885 |
| US-20250092047-A1 | SUBSTITUTED [1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS | PDE12, PDE2A, TDP2 | DRD4 1166/4885DRD2 662/4885DRD3 1370/4885 |
| US-20240309003-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | DRD4 2732/4885DRD2 1052/4885DRD3 2484/4885 |
| US-12552796-B2 | EED inhibitor, and preparation method therefor and use thereof | HSD11B1, CYP4A11, CYP8B1 | DRD4 2050/4885DRD2 797/4885DRD3 871/4885 |
| US-20040198780-A1 | Inhibitors of cathepsin S | CTSS, CTSK, CTSE | DRD4 4490/4885DRD2 4032/4885DRD3 3449/4885 |
| US-20240368195-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SOD1, SMN1; SMN2, CLN6 | DRD4 3963/4885DRD2 4129/4885DRD3 4085/4885 |
| US-12630556-B2 | Substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as PDE2 inhibitors | PDE1A, PDE12, PDE1B | DRD4 389/4885DRD2 210/4885DRD3 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.